The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

Covid-19 Vaccines — Immunity, Variants, Boosters | New England Journal of Medicine Skip to
main content The New England Journal of Medicine homepage Advanced Search SEARCH …

The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

Antibodies against epitopes in S1 give the most accurate CoP against infection by the SARS‐
CoV‐2 coronavirus. Measurement of those antibodies by neutralization or binding assays …

Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …

Anosmia, the loss of smell, is a common and often the sole symptom of COVID-19. The onset
of the sequence of pathobiological events leading to olfactory dysfunction remains obscure …

Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …

Many SARS-CoV-2 variants with naturally acquired mutations have emerged. These
mutations can affect viral properties such as infectivity and immune resistance. Although the …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

The zoonotic SARS-CoV-2 virus that causes COVID-19 continues to spread worldwide, with
devastating consequences. While the medical community has gained insight into the …